EP Patent

EP4251165A1 — Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection

Assigned to Deciphera Pharmaceuticals LLC · Expires 2023-10-04 · 3y expired

What this patent protects

Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor.

USPTO Abstract

Described herein, in part, are methods of treating viral infections, such as coronavirus infections, in patients in need thereof, comprising administering to the patients a VPS34 inhibitor.

Drugs covered by this patent

Patent Metadata

Patent number
EP4251165A1
Jurisdiction
EP
Classification
—
Expires
2023-10-04
Drug substance claim
No
Drug product claim
No
Assignee
Deciphera Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.